The Role of Surgery for Nodular Hyperthyroidism

  • Dawn M. Elfenbein
  • David F. SchneiderEmail author


The management of nodules in the setting of hyperthyroidism presents a challenge for the clinician and patient. The workup should focus on distinguishing the three main etiologies of hyperthyroidism: Graves’ disease, toxic multinodular goiter, and toxic solitary nodule. The primary imaging consists of ultrasound and radioactive iodine uptake scanning. Additional workup aims to rule out the presence of cancer in any of the nodules. This is accomplished via fine needle aspiration (FNA) biopsy. When choosing the definitive treatment strategy, surgery becomes an attractive solution because it eliminates the need for future surveillance of the nodules, alleviates compressive symptoms from the nodules or goiter, and resolves any current or future concern about thyroid cancer.


Hyperthyroidism Thyroid nodules Graves’ disease Toxic multinodular goiter Toxic solitary nodule Fine needle aspiration (FNA) biopsy Surgery Radioactive iodine Thyroidectomy Thyroid cancer 


  1. 1.
    Panneerselvan R, Schneider DF, Sippel RS, Chen H. Radioactive iodine scanning is not beneficial but its use persists for euthyroid patients. J Surg Res. 2013;184(1):269–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Okosieme OE, Chan D, Price SA, Lazarus JH, Premawardhana LD. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol (Oxf). 2010;72(1):122–7.CrossRefGoogle Scholar
  3. 3.
    Weetman AP. Grave’s disease 1835–2002. Horm Res. 2003;59 Suppl 1:114–8.PubMedGoogle Scholar
  4. 4.
    Carnell NE, Valente WA. Thyroid nodules in Graves’ disease: classification, characterization, and response to treatment. Thyroid. 1998;8(8):647–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Tam AA, Kaya C, Kilic FB, Ersoy R, Cakir B. Thyroid nodules and thyroid cancer in Graves’ disease. Arq Bras Endocrinol Metabol. 2014;58(9):933–8.PubMedGoogle Scholar
  6. 6.
    Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81(8):2986–93.PubMedGoogle Scholar
  7. 7.
    Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456–520.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves’ disease. Clin Endocrinol (Oxf). 2004;60(6):719–25.CrossRefGoogle Scholar
  9. 9.
    Lee J, Nam KH, Chung WY, Soh EY, Park CS. Clinicopathologic features and treatment outcomes in differentiated thyroid carcinoma patients with concurrent Graves’ disease. J Korean Med Sci. 2008;23(5):796–801.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nys P, Cordray JP, Sarafian V, Lefort-Mosse E, Merceron RE. Screening for thyroid cancer according to French recommendations with thyroid ultrasound in newly diagnosed Graves’ disease without palpable nodule is not useful. Ann Endocrinol (Paris). 2015;76(1):13–8.CrossRefGoogle Scholar
  11. 11.
    Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”–screening and overdiagnosis. N Engl J Med. 2014;371(19):1765–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefPubMedGoogle Scholar
  13. 13.
    Castagna MG, Belardini V, Memmo S, Maino F, Di Santo A, Toti P, et al. Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J Clin Endocrinol Metab. 2014;99(9):3193–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168(1):1–4.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ozaki O, Ito K, Mimura T, Sugino K, Kitamura Y, Iwabuchi H, et al. Thyroid carcinoma after radioactive iodine therapy for Graves’ disease. World J Surg. 1994;18(4):518–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg. 2010;34(6):1261–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Al-Adhami A, Snaith AC, Craig WL, Krukowski ZH. Changing trends in surgery for Graves’ disease: a cohort comparison of those having surgery intended to preserve thyroid function with those having ablative surgery. J Otolaryngol. 2013;42:37.Google Scholar
  18. 18.
    Feroci F, Rettori M, Borrelli A, Coppola A, Castagnoli A, Perigli G, et al. A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves’ disease. Surgery. 2014;155(3):529–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Oltmann SC, Brekke AV, Schneider DF, Schaefer SC, Chen H, Sippel RS. Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol. 2015;22(3):952–8.Google Scholar
  20. 20.
    Elfenbein DM, Scheri R, Roman S, Sosa JA. Detection and management of cervical lymph nodes in papillary thyroid cancer. Expert Rev Endocrinol Metabol. 2013;8(4):365–78.Google Scholar
  21. 21.
    Mok VM, Oltmann SC, Chen H, Sippel RS, Schneider DF. Identifying predictors of a difficult thyroidectomy. J Surg Res. 2014;190(1):157–63.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ritter K, Elfenbein D, Schneider DF, Chen H, Sippel RS. Hypoparathyroidism after total thyroidectomy: incidence and resolution. J Surg Res. 2015;197(2):348–53.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126(3):226–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med. 1990;89(5):602–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010;322(1–2):125–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust. 1996;164(4):200–3.PubMedGoogle Scholar
  27. 27.
    American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefGoogle Scholar
  28. 28.
    Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646.CrossRefPubMedGoogle Scholar
  29. 29.
    Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer’s disease): surgery versus radioiodine. Surgery. 2002;132(6):916–23; discussion 23.CrossRefPubMedGoogle Scholar
  30. 30.
    Cerci C, Cerci SS, Eroglu E, Dede M, Kapucuoglu N, Yildiz M, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007;53(3):157–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Smith JJ, Chen X, Schneider DF, Nookala R, Broome JT, Sippel RS, et al. Toxic nodular goiter and cancer: a compelling case for thyroidectomy. Ann Surg Oncol. 2013;20(4):1336–40.CrossRefPubMedGoogle Scholar
  32. 32.
    Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91(9):3411–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Chen AY, Bernet VJ, Carty SE, Davies TF, Ganly I, Inabnet 3rd WB, et al. American Thyroid Association statement on optimal surgical management of goiter. Thyroid. 2014;24(2):181–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Stang MT, Armstrong MJ, Ogilvie JB, Yip L, McCoy KL, Faber CN, et al. Positional dyspnea and tracheal compression as indications for goiter resection. Arch Surg. 2012;147(7):621–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Porterfield Jr JR, Thompson GB, Farley DR, Grant CS, Richards ML. Evidence-based management of toxic multinodular goiter (Plummer’s Disease). World J Surg. 2008;32(7):1278–84.CrossRefPubMedGoogle Scholar
  36. 36.
    Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, et al. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005;15(11):1279–86.CrossRefPubMedGoogle Scholar
  37. 37.
    Sztal-Mazer S, Nakatani VY, Bortolini LG, Boguszewski CL, Graf H, de Carvalho GA. Evidence for higher success rates and successful treatment earlier in Graves’ disease with higher radioactive iodine doses. Thyroid. 2012;22(10):991–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014;21(13):4174–80.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280(4):347–55.CrossRefPubMedGoogle Scholar
  40. 40.
    Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109(10):1972–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004;14(11):933–45.CrossRefPubMedGoogle Scholar
  42. 42.
    Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf). 1999;50(2):197–202.CrossRefGoogle Scholar
  43. 43.
    Vaiman M, Nagibin A, Hagag P, Kessler A, Gavriel H. Hypothyroidism following partial thyroidectomy. Otolaryngol Head Neck Surg. 2008;138(1):98–100.CrossRefPubMedGoogle Scholar
  44. 44.
    Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med. 1983;309(24):1473–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer’s disease). Exp Clin Endocrinol Diabetes. 1998;106 Suppl 4:S78–84.CrossRefPubMedGoogle Scholar
  46. 46.
    van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Invest. 1992;15(11):797–800.CrossRefPubMedGoogle Scholar
  47. 47.
    Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84(10):3636–41.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of California, IrvineIrvineUSA
  2. 2.Section of Endocrine Surgery, Department of SurgeryUniversity of WisconsinMadisonUSA

Personalised recommendations